Saturday 17 October 2026
Export CTOR’s income statement to Excel — free account
Citius Oncology, Inc.
CTOR Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, EPS was flat, free cash flow was flat and total debt rose 79.3%, each against the same quarter a year earlier.
0.75
0.00
0.00%
Follow CTOR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | 0.00 | 0.00 | 0.00 | |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
— | (11.89) | (16.19) | (25.87) | |
P/B ratio |
— | 1.50 | 1.76 | 1.74 | |
Price to Tangible BV |
— | 1.50 | 1.76 | 1.74 | |
EV/Sales |
— | 0.00 | 0.00 | 0.00 | |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
— | (7.43) | (4.28) | (3.80) | |
EV/FCF |
— | (4.15) | (2.60) | (2.29) | |
Quick Ratio |
0.08 | 0.25 | 0.06 | 0.29 | |
Current Ratio |
0.56 | 0.83 | 0.50 | 0.73 | |
Net Debt/EBITDA |
(1.99) | (1.71) | (0.35) | (0.53) | |
Debt/Assets |
13.19% | 13.91% | 11.94% | 18.02% | |
Debt/Equity |
0.30 | 0.26 | 0.34 | 0.50 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.10 | 1.33 | 0.14 | 0.30 | |
Capex/Depreciation |
0.00 | (7.67) | (0.35) | (1.05) | |
Interest Coverage |
(82.23) | (114.68) | (867.08) | (37.62) | |
Research and Development Expense of Revenue |
0.00% | 25.82% | 64.74% | 14.63% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 172.80% | 1,628.53% | 520.82% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 100.30% | 211.52% | 238.37% | |
Graham Net Nets |
— | (0.16) | (0.58) | (0.41) | |
Graham Number |
— | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
— | (31.00%) | (75.81%) | (72.31%) | |
Free Cash Flow Yield |
— | (26.29%) | (44.23%) | (45.83%) | |
Revenue per Share |
0.00 | 0.05 | 0.02 | 0.01 | |
Operating CF per Share |
(0.07) | (0.08) | (0.04) | (0.03) | |
Capex per Share |
(0.08) | (0.05) | (0.01) | (0.02) | |
Free Cash Flow per Share |
(0.15) | (0.13) | (0.04) | (0.04) | |
Cash per Share |
0.05 | 0.08 | 0.03 | 0.15 | |
Shareholders Equity per Share |
0.61 | 0.67 | 0.35 | 0.37 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.61 | 0.67 | 0.35 | 0.37 | |
Free Cash Flow |
(11.24) | (11.75) | (4.43) | (4.71) | |
Working Capital |
(21.95) | (7.56) | (29.39) | (16.08) | |
Capital Expenditures |
(5.75) | (4.40) | (0.60) | (2.00) | |
Net Current Asset Value |
(28.53) | (14.41) | (36.01) | (29.00) | |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 1.12 | 0.36 | 1.34 | |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
8.47 | 8.16 | 8.28 | 7.99 | |
Average Inventory |
15.28 | 18.51 | 19.00 | 19.92 | |
Average Assets |
92.66 | 100.23 | 96.07 | 101.90 | |
Average Common Equity |
45.50 | 49.85 | 35.46 | 36.39 |
Columns are period end dates · fundamentals updated 5 Oct 2026